Reducing severe Breathlessness with Dronabinol in the severe and very severe chronic obstructive pulmonary disease patient group

Sofie Wolsing

Organization

Vejle Hospital, Denmark.

Team

Sofie Wolsing (PhD student, RN)

Project Description & Objectives

This randomized, double-blinded, crossover trial aims to investigate whether Dronabinol, a form of THC, reduces severe breathlessness in patients with Chronic Obstructive Pulmonary Disease compared to placebo.

The study is registered at www.ClinicalTrials.gov; NCT06473701 and The European Union Clinical Trials Registry: EU CT number 2024-513593-22-00.

Data Collection Process

Patients assess their breathlessness every day, which are the primary effect parameter. In addition, they use the Garmin watches to collect further information on activity, respiratory and sleep parameters during the study period.

Fitrockr Utilization

We use the Garmin Venu 3 watches for 6 days in the baseline period, and under full medication dose in both treatment arms (Dronabinol and Placebo). Fitrockr was used to extract and analyze the Garmin data.

Wearable Used

Venu 3

Number of Participants

Duration

24 months

Metrics Collected

Daily Activity Data

Steps

Heart Rate

HRV

Stress

Skin Temperature